Q4 2024 Neogenomics Inc Earnings Call Transcript
Key Points
- NeoGenomics Inc (NEO) achieved double-digit revenue growth for the ninth consecutive quarter, with Q4 revenue reaching $172 million.
- Clinical testing volumes increased by 9% year-over-year, with a 5% increase in revenue per test.
- Adjusted gross margins improved to 48%, marking the highest level in 20 quarters.
- NGS (Next-Generation Sequencing) revenue grew by 24% in Q4 and 34% for the year, now representing over 30% of total revenue.
- NeoGenomics Inc (NEO) served nearly 700,000 patients in 2024, positioning the company well to achieve its goal of serving 1 million patients annually by 2028.
- The pharma segment did not experience the expected year-end budget flush, leading to a softer quarter for that business line.
- NeoGenomics Inc (NEO) faced limitations in selling new RaDaR contracts due to ongoing litigation, impacting revenue potential.
- The company anticipates a weaker Q1 2025 due to typical seasonality and increased investments in the first half of the year.
- Despite growth in NGS, the overall non-clinical revenue, including pharma, was down 7% for the year.
- The ongoing RaDaR litigation poses a risk, with a jury trial scheduled for October 2025, potentially affecting future business operations.
Welcome to the NeoGenomics fourth-quarter and full-year 2024 financial results conference call and webcast. At this time, all participants are on a listen-only mode. Please note this call is being recorded and an audio replay will be available on the company's website.
Kendra Sweeney, Vice President of Investor Relations, you may begin your conference.
Thank you, Holly. Good morning, everyone, and welcome to the NeoGenomics fourth-quarter and full-year 2024 financial results call. With me today to discuss the results are Chris Smith, Chief Executive Officer; Jeff Sherman, Chief Financial Officer; Warren Stone, Chief Commercial Officer; and Andrew Lukowiak, Chief Innovation Officer. Additional members of the management team are available for Q&A, including Melody Harris, Chief Operations Officer; and Kareem Saad, Head of Strategy and Transformation. This call is being simultaneously webcast, and we'll be referring to a slide presentation that has been posted to the Investors tab
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
